These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 18250636)

  • 1. Cardiometabolic features of polycystic ovary syndrome.
    Hoffman LK; Ehrmann DA
    Nat Clin Pract Endocrinol Metab; 2008 Apr; 4(4):215-22. PubMed ID: 18250636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance.
    Bethea SW; Nestler JE
    Panminerva Med; 2008 Dec; 50(4):295-304. PubMed ID: 19078870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Economou F; Palimeri S; Christakou C
    Ann N Y Acad Sci; 2010 Sep; 1205():192-8. PubMed ID: 20840272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome.
    Dhindsa G; Bhatia R; Dhindsa M; Bhatia V
    J Postgrad Med; 2004; 50(2):140-4. PubMed ID: 15235215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary syndrome and the metabolic syndrome.
    Weerakiet S
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S189-93. PubMed ID: 21213522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and polycystic ovary syndrome.
    Galluzzo A; Amato MC; Giordano C
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance in patients with polycystic ovary syndrome.
    Schröder AK; Tauchert S; Ortmann O; Diedrich K; Weiss JM
    Ann Med; 2004; 36(6):426-39. PubMed ID: 15513294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors.
    Lakhani K; Prelevic GM; Seifalian AM; Atiomo WU; Hardiman P
    J Obstet Gynaecol; 2004 Sep; 24(6):613-21. PubMed ID: 16147598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of insulin sensitizers in polycystic ovarian syndrome.
    Baillargeon JP
    Curr Opin Investig Drugs; 2005 Oct; 6(10):1012-22. PubMed ID: 16259222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options of polycystic ovary syndrome in adolescence.
    Zapanti E; Kiapekou E; Loutradis D
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():208-13. PubMed ID: 16641862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
    Tomlinson J; Millward A; Stenhouse E; Pinkney J
    Diabet Med; 2010 May; 27(5):498-515. PubMed ID: 20536945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives of insulin resistance and polycystic ovary syndrome.
    Pauli JM; Raja-Khan N; Wu X; Legro RS
    Diabet Med; 2011 Dec; 28(12):1445-54. PubMed ID: 21950959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic syndrome in polycystic ovary syndrome.
    Essah PA; Wickham EP; Nestler JE
    Clin Obstet Gynecol; 2007 Mar; 50(1):205-25. PubMed ID: 17304037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome.
    Tasali E; Van Cauter E; Hoffman L; Ehrmann DA
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3878-84. PubMed ID: 18647805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Expert Opin Ther Targets; 2009 Oct; 13(10):1205-26. PubMed ID: 19650762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
    Sharma ST; Nestler JE
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):245-60. PubMed ID: 16772155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk in women with polycystic ovary syndrome.
    Cho LW; Atkin SL
    Minerva Endocrinol; 2007 Dec; 32(4):263-73. PubMed ID: 18091663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.